One of the persistent anxieties surrounding GLP-1 receptor agonists—whether in clinic or in the laboratory—is that rapid fat loss can carry a measurable lean-tissue penalty. Body-weight graphs look impressive; grip strength and soleus cross-section sometimes tell a different story. A preprint posted in late June 2026, and subsequently discussed at two university journal clubs, has revived interest in metabolic co-factors as a way to soften that trade-off in controlled animal models.
Study design
The investigators used 64 male Sprague-Dawley rats divided into four arms: vehicle, ketone ester alone, semaglutide alone, and semaglutide plus oral (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone ester (KE). Semaglutide was dosed subcutaneously three times weekly at a scaled exposure intended to mimic therapeutic plasma Cmax ranges seen in published rodent obesity studies. KE was delivered in drinking water at a concentration adjusted daily to target blood β-hydroxybutyrate of 0.5–1.0 mmol/L—high enough to shift substrate utilization, low enough to avoid ketoacidosis markers.
The run-in lasted fourteen weeks. Dual-energy X-ray absorptiometry (DEXA) scans were taken at baseline, week 8, and week 14. Forelimb grip strength was assessed on a digital force transducer every two weeks. At termination, gastrocnemius and soleus muscles were weighed, flash-frozen, and analyzed for phosphorylated AMPK, FoxO3a localization, and ubiquitin-proteasome pathway markers (MuRF1 and atrogin-1 mRNA).
Results: fat down, muscle partly spared
Semaglutide monotherapy reduced total body mass by 18.4% versus vehicle at week 14, with fat mass accounting for most of the change. Lean mass still declined by 6.1%—consistent with prior literature. The combination arm lost 17.2% total mass (not statistically different from semaglutide alone on fat endpoints) but lean-mass decline was limited to 2.3%, a significant attenuation. Grip strength dropped 11% with semaglutide alone; the combination arm recovered to within 4% of vehicle controls.
At the molecular level, semaglutide increased atrogin-1 transcript levels in soleus tissue; KE co-treatment blunted that induction without fully reversing semaglutide's effect on fat pad weight. Phospho-AMPK was elevated in the combination group, leading the authors to hypothesize that ketone bodies provide an alternative oxidative substrate during caloric deficit, reducing catabolic signaling in fast-twitch fibers.
Limitations the authors acknowledge
The team was explicit about boundaries: this is a rodent model with scaled dosing, not a human protocol. KE palatability required acclimation; water intake variability introduced noise. Female animals were not studied. There was no exercise intervention arm— relevant because voluntary wheel running has independently shown lean-mass protection in some GLP-1 studies.
Peer review was pending at the time of publication of this news item. Even if replicated, the findings would not establish a clinical recommendation; they do, however, give laboratory groups a structured hypothesis to test with analytically characterized semaglutide lots and documented ketone exposure metrics.
What peptide purchasers should note
Combination studies amplify quality requirements. When semaglutide purity, related peptides, or oxidation products drift between lots, combination arms become impossible to reproduce across institutions. Buyers should demand batch-specific COAs with LC-MS identity, net peptide content by nitrogen analysis or amino acid analysis, and endotoxin reporting for any in vivo laboratory work performed under IACUC approval.
Radiptide supplies semaglutide and related research peptides strictly for laboratory and in vitro use unless a customer holds appropriate institutional approvals for animal research; our materials are not intended for human consumption or compounding into drug products.